Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies

BIO-PATH HOLDINGS, INC.

Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.
Phase 1/1b BP1001-A advanced to dose level 2; expects dose level 3 by year-end.
Phase 1/1b BP1002 completed second dose cohort (40 mg/m2); advancing to dose level 3 in Q4 2024.
Developed molecular biomarkers for prexigebersen; preparing preclinical obesity studies.
Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort; results expected year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.